FUKOKU MUTUAL LIFE INSURANCE Co maintained its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,200 shares of the medical research company’s stock at the end of the second quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Quest Diagnostics were worth $245,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Meeder Asset Management Inc. raised its stake in shares of Quest Diagnostics by 55.9% in the 2nd quarter. Meeder Asset Management Inc. now owns 34,817 shares of the medical research company’s stock valued at $3,870,000 after acquiring an additional 12,478 shares during the period. Bank of America Corp DE lifted its holdings in shares of Quest Diagnostics by 0.6% in the 1st quarter. Bank of America Corp DE now owns 1,887,303 shares of the medical research company’s stock worth $185,315,000 after acquiring an additional 11,399 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Quest Diagnostics by 4.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 487,316 shares of the medical research company’s stock worth $54,171,000 after acquiring an additional 18,968 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Quest Diagnostics by 12.7% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 33,104 shares of the medical research company’s stock worth $3,680,000 after acquiring an additional 3,719 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Quest Diagnostics by 76.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,144,504 shares of the medical research company’s stock worth $127,223,000 after acquiring an additional 494,535 shares during the last quarter. Institutional investors and hedge funds own 87.10% of the company’s stock.

A number of equities analysts recently weighed in on DGX shares. UBS AG increased their price objective on shares of Quest Diagnostics from $115.00 to $123.00 and gave the stock a “buy” rating in a research report on Thursday, July 6th. Barclays PLC reissued a “hold” rating and issued a $110.00 target price on shares of Quest Diagnostics in a research report on Wednesday, July 19th. Evercore ISI reissued an “in-line” rating and issued a $104.50 target price on shares of Quest Diagnostics in a research report on Wednesday, June 28th. BidaskClub upgraded Quest Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, Piper Jaffray Companies upped their price target on Quest Diagnostics to $107.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, ten have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Quest Diagnostics currently has an average rating of “Hold” and a consensus target price of $110.41.

ILLEGAL ACTIVITY NOTICE: “Quest Diagnostics Incorporated (DGX) Position Held by FUKOKU MUTUAL LIFE INSURANCE Co” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/quest-diagnostics-incorporated-dgx-position-held-by-fukoku-mutual-life-insurance-co/1605597.html.

In other news, Director Jeffrey M. Leiden sold 296 shares of the business’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $106.66, for a total transaction of $31,571.36. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at $639,960. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey M. Leiden sold 1,304 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $108.73, for a total transaction of $141,783.92. Following the transaction, the director now directly owns 6,296 shares in the company, valued at $684,564.08. The disclosure for this sale can be found here. Insiders sold 161,996 shares of company stock valued at $17,517,207 in the last ninety days. 1.75% of the stock is owned by corporate insiders.

Quest Diagnostics Incorporated (NYSE:DGX) traded down 0.76% during mid-day trading on Tuesday, hitting $92.86. 444,420 shares of the company were exchanged. The firm has a 50 day moving average price of $103.85 and a 200 day moving average price of $105.27. The stock has a market cap of $12.67 billion, a price-to-earnings ratio of 18.71 and a beta of 0.66. Quest Diagnostics Incorporated has a 12 month low of $79.12 and a 12 month high of $112.97.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.42 by $0.13. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. Quest Diagnostics’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.34 EPS. Analysts anticipate that Quest Diagnostics Incorporated will post $5.67 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Tuesday, October 3rd will be given a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 1.92%. The ex-dividend date is Monday, October 2nd. Quest Diagnostics’s dividend payout ratio (DPR) is 36.29%.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.